Application of liriodendron chinense or liriodendron chinense extract to preparation of medicine for reducing serum uric acid level and preventing and treating uric acid nephropathy

A technology of serum uric acid and Liriodendron, applied in the field of medicine, can solve problems such as lowering serum uric acid levels

Active Publication Date: 2021-04-27
SICHUAN CREATION PHARM TECH CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, whether it has the effect of reducing serum uric acid le

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of liriodendron chinense or liriodendron chinense extract to preparation of medicine for reducing serum uric acid level and preventing and treating uric acid nephropathy
  • Application of liriodendron chinense or liriodendron chinense extract to preparation of medicine for reducing serum uric acid level and preventing and treating uric acid nephropathy
  • Application of liriodendron chinense or liriodendron chinense extract to preparation of medicine for reducing serum uric acid level and preventing and treating uric acid nephropathy

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0031] Preparation of Liriodendron tulipifera extract: Take 500 g of Liriodendron tulipifera (comprising bark branches and leaves) in 5 L of 75% v / v ethanol aqueous solution, heat and boil for 3 hours, filter, and evaporate the solvent to obtain a brown solid extract.

[0032] Experimental method: Male C57BL / 6 mice were randomly divided into normal group, model group, positive control group (allopurinol 10mg / kg / d), low-dose treatment group of Liriodendron tulipifera extract (250mg / kg / d) and Palm tree extract high-dose treatment group (500mg / kg / d), 6 rats in each group. Adenine (160mg / kg / d) plus oxonate potassium (2400mg / kg / d) was used to establish the model by intragastric administration of mice in each model group and treatment group, and the normal group was intragastrically administered with equal volume of double distilled water for continuous modeling 3 weeks. Simultaneously with modeling, each treatment group was administered intragastrically with Liriodendron chinensis...

Embodiment 1

[0033] Example 1 Liriodendron lowers serum uric acid and prevents and treats the effect of uric acid nephropathy

[0034] Blood samples from mice were centrifuged at room temperature at 3000r / min for 15 minutes, and serum was taken to determine biochemical indicators; mouse urine samples were centrifuged at room temperature at 800g / min for 10 minutes, and the upper layer of urine was taken to determine urinary microalbumin levels. Among them, blood creatinine and blood BUN were detected by automatic biochemical analyzer (TC6010L, Jiangxi Tecom Technology Co., Ltd.); blood uric acid and urine microalbumin were detected by automatic biochemical analyzer (BS-240, Shenzhen Mindray Biomedical Electronics Co., Ltd. ) detection. See the experimental results figure 1 . PAS staining was performed on mouse kidney tissue, the results are shown in figure 2 .

[0035] From figure 1 It can be seen that Liriodendron can significantly reduce serum uric acid levels and improve kidney fun...

Embodiment 2

[0037] Example 2 The improvement effect of Liriodendron chinensis on chronic uric acid renal fibrosis

[0038] MASSON staining was used to evaluate the expression of collagen fibers in the kidney, and renal α-SMA (α-smooth muscle actin) immunohistochemical staining was performed at the same time. See the experimental results image 3 . Kidney Westernblot results see Figure 4 .

[0039] From image 3 It can be seen that after treatment with Liriodendron chinensis, the degree of renal interstitial fibrosis in hyperuricemia mice has been significantly improved. α-SMA immunohistochemical staining showed that Liriodendron can effectively inhibit the expression of stromal α-SMA.

[0040] From Figure 4 It can be seen that the expressions of collagen fiber 1, fibronectin, and α-smooth muscle actin in the kidneys of hyperuric mice were significantly increased, and their expressions in the kidneys could be significantly reduced after treatment with Liriodendron chinensis.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of liriodendron chinense or a liriodendron chinense extract thereof to preparation of a medicine for reducing serum uric acid level and preventing and treating uric acid nephropathy, and belongs to the field of medicines. On one hand, the invention provides an application of the liriodendron chinense or the liriodendron chinense extract to preparation of the medicine for reducing the blood uric acid level. On the other hand, the invention further provides an application of the liriodendron chinense or the liriodendron chinense extract to preparation of a medicine for treating and/or preventing uric acid nephropathy. Animal experiments prove that the liriodendron chinense can obviously reduce the serum uric acid level and improve the degrees of renal tubule expansion, glomerular sclerosis and renal interstitial fibrosis of hyperuricemia mice. Further research shows that the liriodendron chinense plays a role in reducing serum uric acid level by promoting excretion of kidney uric acid. The application provided by the invention can provide a new medication choice for clinically treating hyperuricemia and hyperuricemia nephropathy caused by the hyperuricemia.

Description

technical field [0001] The invention relates to the application of Liriodendron tulipifera or its extract in the preparation of medicines for reducing serum uric acid level and preventing and treating uric acid nephropathy, which belongs to the field of medicine. Background technique [0002] Hyperuricemia refers to a normal purine diet, and the fasting serum uric acid level is measured twice on different days ≥ 416 μmol / L (7 mg / dl) for men and ≥ 357 μmol / L (6 mg / dl) for women. In recent years, many studies at home and abroad have confirmed that hyperuricemia is closely related to the occurrence and development of gout, cardiovascular disease, metabolic syndrome, hypertension and kidney disease. Hyperuricemia is an important reason for the increased prevalence of Chronic Kidney Disease (CKD) and is an independent risk factor for the progression of CKD. Studies have shown that lowering blood uric acid levels can slow the progression of kidney disease. The treatment of hyper...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/57A61P19/06A61P13/12A61K125/00A61K129/00A61K135/00A61K127/00
CPCA61K36/57A61P19/06A61P13/12A61K2236/333A61K2236/51
Inventor 马良付平
Owner SICHUAN CREATION PHARM TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap